866-997-4948(US-Canada Toll Free)

Retinal Biologics Market: Global Industry Analysis 2013-2017 and Opportunity Assessment 2018-2028

Published By :

Future Market Insights

Published Date : Jan 2019

Category :

Healthcare

No. of Pages : 194 Pages

FMI’s recently published report titled ‘Retinal Biologics Market: Global Industry Analysis 2013 – 2017 & Opportunity Assessment 2018 – 2028' offers a comprehensive assessment of the key dynamics pertaining to the retinal biologics market. The report presents growth prospects for the retinal biologics market, which have been obtained with maximum precision through detailed research on the historic as well as current growth parameters.

The report discusses the prominent factors that are likely to have a significant impact on the development of the retinal biologics market during the forecast period. This information will prove to be key for market players to modify their manufacturing and marketing strategies and envisage maximum growth in the retinal biologics market in the coming years.

Chapter 1 – Executive Summary

The report commences with an executive summary, which comprises a summary of the key findings and statistics pertaining to the retinal biologics market. This section also provides market value (US$ Million) estimates for the leading segments of the retinal biologics market.

Chapter 2 – Market Overview

Readers can find a detailed taxonomy and definitions in this chapter to help them better understand the basic information about the retinal biologics market dynamics, pricing analysis, list of key manufacturers and key regulation policies included in the succeeding sections of the report.

Chapter 3 – Global Retinal Biologics Market Analysis 2013 – 2017 & Opportunity Assessment 2018 – 2028 by Drug Class

On the basis of drug class, the retinal biologics market has been segmented into VEGF-A antagonist and TNF-? inhibitor. In this chapter, readers can find information about the key trends and developments observed in the retinal biologics market. The section also comprises a market attractiveness analysis of the segments on the basis of drug class.

Chapter 4 – Global Retinal Biologics Market Analysis 2013 – 2017 & Opportunity Assessment 2018 – 2028 by Indication

Based on indication, the retinal biologics market has been segmented into macular degeneration, diabetic retinopathy, diabetic macular edema, uveitis and others. In this section, readers can find information about device usage, key trends and technological developments in the retinal biologics market along with a market attractiveness analysis of the key segments based on indication.

Chapter 5 – Global Retinal Biologics Market Analysis 2013 – 2017 & Opportunity Assessment 2018 – 2028 by Distribution Channel

By distributional channel, the retinal biologics market has been segmented into institutional sales, which has further been sub-segmented into specialty clinics and hospitals and retail sales, which has further been sub-segmented into retail pharmacies and mail order pharmacies. In this chapter, readers can find information about the key trends and developments identified in the retinal biologics market and a market attractiveness analysis of the key segments based on distributional channel.

Chapter 6 – Global Retinal Biologics Market Analysis 2013 – 2017 & Opportunity Assessment 2018 – 2028 by Region

This chapter explains how the retinal biologics market is expected to grow across various geographic regions, such as North America, Latin America, Western Europe, Eastern Europe, Asia Pacific Excluding Japan (APEJ), Japan and the Middle East & Africa (MEA).

Chapter 7 – North America Retinal Biologics Market Analysis 2013 – 2017 & Opportunity Assessment 2018 – 2028

This chapter includes a detailed analysis of the growth of the retinal biologics market, along with a country-wise assessment for various countries in North America, including the U.S. and Canada. Readers can also find information on regional trends, macro-economic factors and market growth on the basis of drug class, indication, distributional channel and country for the retinal biologics market in North America.

Chapter 8 – Latin America Retinal Biologics Market Analysis 2013 – 2017 & Opportunity Assessment 2018 – 2028

Readers can find detailed information about pricing analysis and regional trends impacting the growth of the Latin American retinal biologics market. This chapter also discusses growth prospects for the retinal biologics market in leading LATAM countries, such as Brazil, Mexico and the Rest of the Latin America.

Chapter 9 – Western Europe Retinal Biologics Market Analysis 2013 – 2017 & Opportunity Assessment 2018 – 2028

Readers can find detailed information about the important growth parameters in the retinal biologics market in several European countries, such as Germany, the U.K., France, Italy, Spain and the rest of Western Europe.

Chapter 10 – Eastern Europe Retinal Biologics Market Analysis 2013 – 2017 & Opportunity Assessment 2018 – 2028

Readers can find detailed information about the important growth parameters in the retinal biologics market for several European countries, such as the Russia, Poland and rest of Eastern Europe.

Chapter 11 – APEJ Retinal Biologics Market Analysis 2013 – 2017 & Opportunity Assessment 2018 – 2028

Readers can find thorough information about the various parameters expected to impact the APEC retinal biologics market during the forecast period 2018 – 2028. China, India, Australia and New Zealand, ASEAN, rest of APAC are the leading countries/regions in APEJ and hence, the prime subject of assessment in this chapter.

Chapter 12 – Japan Retinal Biologics Market Analysis 2013 – 2017 & Opportunity Assessment 2018 – 2028

Readers can find information on the important factors expected to make a significant impact on the growth of the retinal biologics market in Japan during the forecast period 2018 – 2028. This chapter provides an overview of the drivers, restraints and trends prevailing in the Japan retinal biologics market.

Chapter 13 – MEA Retinal Biologics Market Analysis 2013 – 2017 & Opportunity Assessment 2018 – 2028

Readers can find detailed information on how the retinal biologics market is expected to grow in major countries/regions of the MEA region, such as GCC Countries, South Africa, and the Rest of MEA during the period 2018 – 2028.

Chapter 14 – Competition Landscape, Company Share, and Company Profiles

In this chapter, readers can find a comprehensive list of all leading stakeholders in the retinal biologics market and detailed information about each company, including company overview, offered products, SWOT analysis, key strategy and recent company developments. The market players featured in the report include Spark Therapeutics, Inc., F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals, Inc., AbbVie Inc., Johnson & Johnson Services, Inc. and Amgen Inc.

Chapter 15 – Assumptions and Acronyms

This chapter of the retinal biologics market report includes a list of acronyms and assumptions that provide a base to the information and statistics included in the report.

Chapter 16 – Research Methodology

This chapter help readers understand the research methodology followed to obtain various conclusions, important qualitative information and quantitative information about the retinal biologics market.

1. Executive Summary
1.1. Market Overview
1.2. Market Analysis
1.3. FMI Analysis and Recommendations
1.4. Wheel of Fortune

2. Market Introduction
2.1. Market Taxonomy
2.2. Market Definition

3. Global Economic Outlook
3.1. Gross Domestic Indication Type by Region & Country, 2006 – 2021
3.2. Global Healthcare Market Indicators

4. Market Opportunity Analysis
4.1. Macro-Economic Factors
4.2. Opportunity Analysis

5. Market Dynamics
5.1. Drivers
5.1.1. Supply Side Drivers
5.1.2. Demand Side Drivers
5.2. Restraints
5.3. Trends

6. Key Inclusion
6.1. Key Regulations
6.2. Reimbursement Scenario
6.3. Pricing Analysis

7. North America Retinal Biologics Market Analysis 2013–2017 and Forecast 2018–2028
7.1. Introduction
7.2. Historical Market Size (US$ Mn) Analysis by Country, 2013-2017
7.2.1. U.S.
7.2.2. Canada
7.3. Market Size (US$ Mn) Forecast By Country, 2018-2028
7.4. Historical Market Size (US$ Mn) and Trend Analysis by Drug Class, 2013-2017
7.4.1. VEGF-An antagonist
7.4.2. TNF-? inhibitor
7.5. Market Size (US$ Mn) Forecast By Drug Class, 2018-2028
7.6. Historical Market Size (US$ Mn) and Trend Analysis by Indication, 2013-2017
7.6.1. Macular Degeneration
7.6.2. Diabetic Retinopathy
7.6.3. Diabetic Macular Edema
7.6.4. Uveitis
7.6.5. Others
7.7. Market Size (US$ Mn) and Forecast By Indication, 2018-2028
7.8. Historical Market Size (US$ Mn) and Trend Analysis by Distributional Channel, 2013-2017
7.8.1. Institutional Sales
7.8.1.1. Specialty Clinics
7.8.1.2. Hospitals
7.8.2. Retail Sales
7.8.2.1. Retail Pharmacies
7.8.2.2. Mail Order Pharmacies
7.9. Market Size (US$ Mn) Forecast By Distributional Channel, 2018-2028
7.10. Market Attractiveness Analysis
7.10.1. By Country
7.10.2. By Drug Class
7.10.3. By Indication
7.10.4. By Distributional Channel
7.11. Drivers and Restraints: Impact Analysis
7.12. Key Market Participants – Intensity Mapping

8. Latin America Retinal Biologics Market Analysis 2013–2017 and Forecast 2018–2028
8.1. Introduction
8.2. Regional Market Trends
8.3. Historical Market Size (US$ Mn) Analysis by Country, 2013-2017
8.3.1. Brazil
8.3.2. Mexico
8.3.3. Argentina
8.3.4. Rest of Latin America
8.4. Market Size (US$ Mn) Forecast By Country, 2018-2028
8.5. Historical Market Size (US$ Mn) and Trend Analysis by Drug Class, 2013-2017
8.5.1. VEGF-A antagonist
8.5.2. TNF-? inhibitor
8.6. Market Size (US$ Mn) Forecast By Drug Class, 2018-2028
8.7. Historical Market Size (US$ Mn) and Trend Analysis by Indication, 2013-2017
8.7.1. Macular Degeneration
8.7.2. Diabetic Retinopathy
8.7.3. Diabetic Macular Edema
8.7.4. Uveitis
8.7.5. Others 
8.8. Market Size (US$ Mn) and Forecast By Indication, 2018-2028
8.9. Historical Market Size (US$ Mn) and Trend Analysis by Distributional Channel, 2013-2017
8.9.1. Institutional Sales
8.9.1.1. Specialty Clinics
8.9.1.2. Hospitals
8.9.2. Retail Sales
8.9.2.1. Retail Pharmacies
8.9.2.2. Mail Order Pharmacies
8.10. Market Size (US$ Mn) Forecast By Distributional Channel, 2018-2028
8.11. Market Attractiveness Analysis
8.11.1. By Country
8.11.2. By Drug Class
8.11.3. By Indication
8.11.4. By Distributional Channel
8.12. Drivers and Restraints: Impact Analysis
8.13. Key Market Participants – Intensity Mapping

9. Western Europe Retinal Biologics Market Analysis 2013–2017 and Forecast 2018–2028
9.1. Introduction
9.2. Historical Market Size (US$ Mn) Analysis by Country, 2013-2017
9.2.1. Germany
9.2.2. U.K
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Western Europe
9.3. Market Size (US$ Mn) Forecast By Country, 2018-2028
9.4. Historical Market Size (US$ Mn) and Trend Analysis by Drug Class, 2013-2017
9.4.1. VEGF-A antagonist
9.4.2. TNF-? inhibitor
9.5. Market Size (US$ Mn) Forecast By Drug Class, 2018-2028
9.6. Historical Market Size (US$ Mn) and Trend Analysis by Indication, 2013-2017
9.6.1. Macular degeneration
9.6.2. Diabetic Retinopathy
9.6.3. Diabetic Macular Edema
9.6.4. Uveitis
9.6.5. Others
9.7. Market Size (US$ Mn) and Forecast By Indication, 2018-2028
9.8. Historical Market Size (US$ Mn) and Trend Analysis by Distributional Channel, 2013-2017
9.8.1. Institutional Sales
9.8.1.1. Specialty Clinics
9.8.1.2. Hospitals
9.8.2. Retail Sales
9.8.2.1. Retail Pharmacies
9.8.2.2. Mail Order Pharmacies
9.9. Market Size (US$ Mn) Forecast By Distributional Channel, 2018-2028
9.10. Market Attractiveness Analysis
9.10.1. By Country
9.10.2. By Drug Class
9.10.3. By Indication
9.10.4. By Distributional Channel
9.11. Drivers and Restraints: Impact Analysis
9.12. Key Market Participants – Intensity Mapping

10. Eastern Europe Retinal Biologics Market Analysis 2013–2017 and Forecast 2018–2028
10.1. Introduction
10.2. Historical Market Size (US$ Mn) Analysis by Country, 2013-2017
10.2.1. Russia
10.2.2. Poland
10.2.3. Rest of Eastern Europe
10.3. Market Size (US$ Mn) Forecast By Country, 2018-2028
10.4. Historical Market Size (US$ Mn) and Trend Analysis by Drug Class, 2013-2017
10.4.1. VEGF-A antagonist
10.4.2. TNF-? inhibitor
10.5. Market Size (US$ Mn) Forecast By Drug Class, 2018-2028
10.6. Historical Market Size (US$ Mn) and Trend Analysis by Indication, 2013-2017
10.6.1. Macular degeneration
10.6.2. Diabetic Retinopathy
10.6.3. Diabetic Macular Edema
10.6.4. Uveitis
10.6.5. Others
10.7. Market Size (US$ Mn) and Forecast By Indication, 2018-2028
10.8. Historical Market Size (US$ Mn) Trend Analysis by Distributional Channel, 2013-2017
10.8.1. Institutional Sales
10.8.1.1. Specialty Clinics
10.8.1.2. Hospitals
10.8.2. Retail Sales
10.8.2.1. Retail Pharmacies
10.8.2.2. Mail Order Pharmacies
10.9. Market Size (US$ Mn) Forecast By Distributional Channel, 2018-2028
10.10. Market Attractiveness Analysis
10.10.1. By Country
10.10.2. By Drug Class
10.10.3. By Indication
10.10.4. By Distributional Channel
10.11. Drivers and Restraints: Impact Analysis
10.12. Key Market Participants – Intensity Mapping

11. Asia Pacific Excluding Japan Retinal Biologics Market Analysis 2013–2017 and Forecast 2018–2028
11.1. Introduction
11.2. Historical Market Size (US$ Mn) Analysis by Country, 2013-2017
11.2.1. China
11.2.2. India
11.2.3. Australia and New Zealand
11.2.4. ASEAN
11.2.5. Rest of APEJ
11.3. Market Size (US$ Mn) Forecast By Country, 2018-2028
11.4. Historical Market Size (US$ Mn) and Trend Analysis by Drug Class, 2013-2017
11.4.1. VEGF-A antagonist
11.4.2. TNF-? inhibitor
11.5. Market Size (US$ Mn) Forecast By Drug Class, 2018-2028
11.6. Historical Market Size (US$ Mn) and Trend Analysis by Indication, 2013-2017
11.6.1. Macular degeneration
11.6.2. Diabetic Retinopathy
11.6.3. Diabetic Macular Edema
11.6.4. Uveitis
11.6.5. Others
11.7. Market Size (US$ Mn) and Forecast By Indication, 2018-2028
11.8. Historical Market Size (US$ Mn) and Trend Analysis by Distributional Channel, 2013-2017
11.8.1. Institutional Sales
11.8.1.1. Specialty Clinics
11.8.1.2. Hospitals
11.8.2. Retail Sales
11.8.2.1. Retail Pharmacies
11.8.2.2. Mail Order Pharmacies
11.9. Market Size (US$ Mn) Forecast By Distributional Channel, 2018-2028
11.10. Market Attractiveness Analysis
11.10.1. By Country
11.10.2. By Drug Class
11.10.3. By Indication
11.10.4. By Distributional Channel
11.11. Drivers and Restraints: Impact Analysis
11.12. Key Market Participants – Intensity Mapping

12. Japan Retinal Biologics Market Analysis 2013–2017 and Forecast 2018–2028
12.1. Introduction
12.2. Historical Market Size (US$ Mn) and Trend Analysis by Drug Class, 2013-2017
12.2.1. VEGF-A antagonist
12.2.2. TNF-? inhibitor
12.3. Market Size (US$ Mn) and Forecast By Drug Class, 2018-2028
12.4. Historical Market Size (US$ Mn) and Trend Analysis by Indication, 2013-2017
12.4.1. Macular degeneration
12.4.2. Diabetic Retinopathy
12.4.3. Diabetic Macular Edema
12.4.4. Uveitis
12.4.5. Others 
12.5. Market Size (US$ Mn) Forecast By Indication, 2018-2028
12.6. Historical Market Size (US$ Mn) Trend Analysis by Distributional Channel, 2013-2017
12.6.1. Institutional Sales
12.6.1.1. Specialty Clinics
12.6.1.2. Hospitals
12.6.2. Retail Sales
12.6.2.1. Retail Pharmacies
12.6.2.2. Mail Order Pharmacies
12.7. Market Size (US$ Mn) Forecast By Distributional Channel, 2018-2028
12.8. Market Attractiveness Analysis
12.8.1. By Drug Class
12.8.2. By Indication
12.8.3. By Distributional Channel
12.9. Drivers and Restraints: Impact Analysis
12.10. Key Market Participants – Intensity Mapping

13. Middle East and Africa Retinal Biologics Market Analysis 2013–2017 and Forecast 2018–2028
13.1. Introduction
13.2. Historical Market Size (US$ Mn) Analysis by Country, 2013-2017
13.2.1. GCC Countries
13.2.2. South Africa
13.2.3. Rest of Middle East and Africa
13.3. Market Size (US$ Mn) Forecast By Country, 2018-2028
13.4. Historical Market Size (US$ Mn) and Trend Analysis by Drug Class, 2013-2017
13.4.1. VEGF-A antagonist
13.4.2. TNF-? inhibitor
13.5. Market Size (US$ Mn) Forecast By Drug Class, 2018-2028
13.6. Historical Market Size (US$ Mn) and Trend Analysis by Indication, 2013-2017
13.6.1. Macular degeneration
13.6.2. Diabetic Retinopathy
13.6.3. Diabetic Macular Edema
13.6.4. Uveitis
13.6.5. Others 
13.7. Market Size (US$ Mn) and Forecast By Indication, 2018-2028
13.8. Historical Market Size (US$ Mn) Trend Analysis by Distributional Channel, 2013-2017
13.8.1. Institutional Sales
13.8.1.1. Specialty Clinics
13.8.1.2. Hospitals
13.8.2. Retail Sales
13.8.2.1. Retail Pharmacies
13.8.2.2. Mail Order Pharmacies
13.9. Market Size (US$ Mn) Forecast By Distributional Channel, 2018-2028
13.10. Market Attractiveness Analysis
13.10.1. By Country
13.10.2. By Drug Class
13.10.3. By Indication
13.10.4. By Distributional Channel
13.11. Drivers and Restraints: Impact Analysis
13.12. Key Market Participants – Intensity Mapping

14. Forecast Factors: Relevance and Impact

15. Forecast Assumptions

16. Competition Analysis
16.1. Competition Dashboard
16.2. Competitors Deep Dive
16.2.1. Spark Therapeutics Inc.
16.2.1.1. Overview
16.2.1.2. Key Financials
16.2.1.3. SWOT Analysis
16.2.1.4. Key Developments
16.2.1.5. Key Strategy
16.2.2. F. Hoffmann-La Roche Ltd
16.2.2.1. Overview
16.2.2.2. Key Financials
16.2.2.3. SWOT Analysis
16.2.2.4. Key Developments
16.2.2.5. Key Strategy
16.2.3. Regeneron Pharmaceuticals, Inc.
16.2.3.1. Overview
16.2.3.2. Key Financials
16.2.3.3. SWOT Analysis
16.2.3.4. Key Developments
16.2.3.5. Key Strategy
16.2.4. AbbVie Inc
16.2.4.1. Overview
16.2.4.2. Key Financials
16.2.4.3. SWOT Analysis
16.2.4.4. Key Developments
16.2.4.5. Key Strategy
16.2.5. Johnson & Johnson Services, Inc
16.2.5.1. Overview
16.2.5.2. Key Financials
16.2.5.3. SWOT Analysis
16.2.5.4. Key Developments
16.2.5.5. Key Strategy
16.2.6. Amgen Inc.
16.2.6.1. Overview
16.2.6.2. Key Financials
16.2.6.3. SWOT Analysis
16.2.6.4. Key Developments
16.2.6.5. Key Strategy

17. Global Retinal Biologics Market Analysis 2013–2017 and Forecast 2018–2028 by Region
17.1. Introduction / Key Findings
17.2. Historical Market Size (US$ Mn) Analysis by Region
17.2.1. North America
17.2.2. Latin America
17.2.3. Western Europe
17.2.4. Eastern Europe
17.2.5. Asia Pacific Excluding Japan 
17.2.7. Japan
17.2.8. Middle East and Africa
17.3. Market Size (US$ Mn) Forecast By Region
17.4. Market Attractiveness Analysis by Region

18. Global Retinal Biologics Market Analysis 2013–2017 and Forecast 2018–2028, By Drug Class
18.1. Introduction/Key Finding
18.2. Historical Market Size (US$ Mn) Analysis by Drug Class, 2013-2017
18.2.1. VEGF-A antagonist
18.2.2. TNF-? inhibitor
18.3. Market Size (US$ Mn) Forecast By Drug Class, 2018-2028
18.4. Market Attractiveness Analysis by Drug Class

19. Global Retinal Biologics Market Analysis 2013–2017 and Forecast 2018–2028, By Indication
19.1. Introduction/Key Finding
19.2. Historical Market Size (US$ Mn) Analysis by Indication, 2013-2017
19.2.1. Macular degeneration
19.2.2. Diabetic Retinopathy
19.2.3. Diabetic Macular Edema
19.2.4. Uveitis
19.2.5. Others 
19.3. Market Size (US$ Mn) Forecast By Indication, 2018-2028
19.4. Market Attractiveness Analysis by Indication

20. Global Retinal Biologics Market Analysis 2013–2017 and Forecast 2018–2028, By Distributional Channel
20.1. Introduction/Key Finding
20.2. Historical Market Size (US$ Mn) Analysis by Distributional Channel, 2013-2017
20.2.1. Institutional Sales
20.2.1.1. Specialty Clinics
20.2.1.2. Hospitals
20.2.2. Retail Sales
20.2.2.1. Retail Pharmacies
20.2.2.2. Mail Order Pharmacies
20.3. Market Size (US$ Mn) Forecast By Distributional Channel, 2018-2028
20.4. Market Attractiveness Analysis by Distributional Channel

21. Global Retinal Biologics Market Analysis 2013–2017 and Forecast 2018–2028
21.1. Global Market Value Analysis (US$ Mn)
21.2. Absolute $ Opportunity

22. Assumptions and Acronyms Used

23. Research Methodology

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *